Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Knock down of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease.

In English

Författare

  • Lazlo Horvath
  • Ingrid van Marion
  • Khalid Tai
  • Troels Tolstrup Nielsen
  • Cecilia Lundberg

Summary, in English

BACKGROUND: Dopamine depletion of the striatum is one of the hallmarks of Parkinson's disease. The loss of dopamine upregulates GAD67 expression in the striatal projection neurons and causes other changes in the activity of the basal ganglia circuit. METHODS: To normalize the GAD67 expression in the striatum after dopamine depletion we developed several lentiviral vectors that express RNAi directed against GAD67 mRNA. The vectors were injected into the striatum of hemiparkinsonian rats and the level of GAD67 protein as well as a marker of neuronal activity, mtCO1, was analyzed using Western blots. RESULTS: Unilateral lesions of the dopamine neurons in substantia nigra resulted in an increased level of GAD67 protein in the ipsilateral striatum. Furthermore, we detected significantly higher levels of mtCO1, after dopamine depletion in the striatum. Using a lentiviral vectors with a synthetic miRNA scaffold to deliver RNAi we were able to normalize the GAD67 protein levels in the parkinsonian rat striatum. In addition, we were able to normalize the increased neural activity, which resulted from the loss of dopamine as measured by the marker mtCO1. CONCLUSIONS: We conclude that RNAi directed against GAD67 may be a valid approach to correct the dysregulation of the basal ganglia circuit in a rat model of Parkinson's disease. The possibility to correct for a loss of dopamine using non-dopamimetic tools is interesting as it may be more directed towards the casual mechanisms of the motor symptoms. Copyright © 2011 John Wiley & Sons, Ltd.

Publiceringsår

2011

Språk

Engelska

Sidor

188-197

Publikation/Tidskrift/Serie

Journal of Gene Medicine

Volym

13

Issue

3

Dokumenttyp

Artikel i tidskrift

Förlag

John Wiley & Sons Inc.

Ämne

  • Neurosciences

Nyckelord

  • 6-hydroxydopamine lesion
  • GAD67
  • lentiviral vector
  • mtCO1
  • Parkinson's
  • disease
  • RNAi
  • striatum
  • synthetic miRNA

Status

Published

Forskningsgrupp

  • CNS Gene Therapy

ISBN/ISSN/Övrigt

  • ISSN: 1521-2254